Fenretinide clinical trials
Also written McN-R-1967, ST-001 and N-(4-hydroxyphenyl)retinamide.
How each study uses Fenretinide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Fenretinide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2000 (5)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1994 | 1 |
| 1995 | 1 |
| 1996 | 1 |
| 1997 | 2 |
| 1998 | 3 |
| 1999 | 1 |
| 2000 | 5 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 35
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (4) · South Plains Oncology Consortium (4) · Laurent Pharmaceuticals Inc. (3) · Island Pharmaceuticals (2) · Eastern Cooperative Oncology Group (2) · California Cancer Consortium (2) · Barbara Ann Karmanos Cancer Institute (2)
Often tested with
Tested in the same studies.
Tamoxifen (2) · Cisplatin (2) · Paclitaxel (2) · Tretinoin (1) · Ketoconazole (1) · Vincristine (1) · Rituximab (1) · Bexarotene (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Fenretinide.
- May 2027Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung CancerPhase 1 · SciTech Development, Inc.
Studies
Open first, then newest update. How each study uses Fenretinide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 44
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruitingPhase 1SciTech Development, Inc.NCT04234048Written as Fenretinide
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung CancerRecruitingPhase 1SciTech Development, Inc.NCT06922539Written as Fenretinide
- N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant NeuroblastomaCompletedPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT00646230Written as fenretinide
- Study of LAU-7b for the Treatment of Long COVID in AdultsCompletedPhase 2/3Laurent Pharmaceuticals Inc.NCT05999435Written as LAU-7b for 3 cycles
- Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in AdultsTerminatedPhase 2/3Laurent Pharmaceuticals Inc.NCT04417257Written as LAU-7b
- Study to Examine the Effects of Oral FenretinideCompletedPhase 2Island PharmaceuticalsNCT06528457Written as ISLA101
- A Study to Evaluate the Safety of Fenretinide in Healthy VolunteersCompletedPhase 1Island PharmaceuticalsNCT06181760Written as Fenretinide
- Study of LAU-7b in the Treatment of Cystic Fibrosis in AdultsCompletedPhase 2Laurent Pharmaceuticals Inc.NCT03265288Written as LAU-7b
- Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus SyndromeCompletedPhase 2Eastern Cooperative Oncology GroupNCT00003601Written as fenretinide
- Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHLTerminatedPhase 1South Plains Oncology ConsortiumNCT01187810Written as Fenretinide
- Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant NeuroblastomaTerminatedPhase 1South Plains Oncology ConsortiumNCT02163356Written as Fenretinide/LXS Oral Powder
- Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed MalignanciesTerminatedPhase 1South Plains Oncology ConsortiumNCT01553071Written as Fenretinide (4-HPR) plus Intravenous Safingol
- A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With ObesitySuspendedPhase 2University of California, San DiegoNCT00546455Written as Fenretinide
- Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian CancerTerminatedPhase 1/2South Plains Oncology ConsortiumNCT01535157Written as Fenretinide/LXS + Ketoconazole
- Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell LymphomasStatus unknownPhase 2CerRx, Inc.NCT02495415Written as Fenretinide
- Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder CancerCompletedPhase 3M.D. Anderson Cancer CenterNCT00004154Written as Fenretinide
- Fenretinide in Healthy Young Women at Genetic and Familial RiskTerminatedPhase 3European Institute of OncologyNCT01479192Written as Fenretinide
- Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT00006471Written as Fenretinide
- Fenretinide in Treating Patients With Cervical NeoplasiaCompletedPhase 3M.D. Anderson Cancer CenterNCT00003075Written as Fenretinide
- Fenretinide in Treating Patients With Recurrent Malignant GliomaCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT00006080Written as fenretinide
See all 44 studies that test Fenretinide →
Given beside what is tested · 1 — Fenretinide is usual care or a partner of the new treatment
Codes
What other systems call Fenretinide · ClinicalTrials.gg INT008581
- MeSH (NLM) D017313FenretinideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 187EJ7QEXLFENRETINIDEConfirmed FDA, NLM, Wikidata
- RxNorm 24870One source Wikidata
- Wikidata Q5443576fenretinideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1098FenretinideOne source FDA
- DrugBank DB05076One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D017313 | Fenretinide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 187EJ7QEXL | FENRETINIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 24870 | — | One source Wikidata |
| Wikidata | Q5443576 | fenretinide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1098 | Fenretinide | One source FDA |
| DrugBank | DB05076 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.